USE OF Ω-3 POLYUNSATURATED FATTY ACIDS FOR TREATMENT OF PAROXYSMAL ATRIAL FIBRILLATION
Abstract
About the Authors
I. V. AntonchenkoRussian Federation
B. A. Tatarskiy
Russian Federation
V. A. Rodionov
Russian Federation
R. E. Batalov
Russian Federation
G. M. Savenkova
Russian Federation
E. V. Borisova
Russian Federation
I. N. Biserova
Russian Federation
S. V. Popov
Russian Federation
References
1. Kannel W., Wolf P., Benjamin E. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates // Am J Cardiol. 1998; 82: 2N-9N.
2. Benajmim E., Levy D., Vaziri S. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study // JAMA 1994;171:840-44.
3. Кушаковский М.С. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика).- Санкт-Петербург 1999; 175 с.
4. Сулимов В.А. Медикаментозная терапия фибрилляции предсердий: настоящее и будущее // Кардиология 1999; 7: 69-75.
5. Wyse D., Waldo A., DiMarco J. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation // N Engl J Med 2002;347:1825-1833.
6. Breithardt G., Kottkamp H., Haverkamp W. et al. Problems with anti-arrhythmia therapy in atrial fibrillation // Сardiol. 1994; 83: 63-69.
7. Carlsson J., Miketic S., Windeler J. et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study // J Am Coll Cardiol 2003; 41: 1690-1696.
8. Van Gelder I., Hagens V., Bosker H., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation // N Engl J Med 2002; 347: 1834-1840.
9. Mannino M., Metha D., Gomes J. Current treatment options for paroxysmal supraventricular tachycardia // Am Heart J 1994; 127: 475-480.
10. ACC/AHA/ESC guidelines for management of patients with atrial fibrillation // Circulation 2001; 104: 2118-2150.
11. Б.А.Татарский. Стратегия «таблетка в кармане» при купировании фибрилляции предсердий // Российский кардиологический журнал, 2005, № 1, с. 45-54.
12. GISSI-Investigators. Dietary supplementation with ω-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: the GISSI-Prevenzione trial // Lancet. 1999; 354: 447-455.
13. Strauss M., Dorian P., Verma S. Fish Oil Supplementation and Arrhythmias // JAMA,2005; 294(17): 2165-2165.
14. Miller J., Zipes D. Management of the patient with cardiac arrhithmias. A textbook of cardiovascular medicine. Philadelphia: W.B.Saunders company. 2001. P. 731-736.
15. Botto G., Bonini W., Broffoni T. et al. Conversion ofrecent onset atrial fibrillation with single loading oral dose of propafenone // Pacing Clin Electrophysiol 1996;19:1939-1943.
16. Capucci A., Boriani G., Botto G. et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide // Am J Cardiol 1994; 74: 503505.
17. Boriani G., Capucci A., Lenzi T. et all. Propafenone for conversion of recent-onset atrial fibrillation: a controlled comparison between oral loading dose and intravenous administration // Chest 1995; 108: 355-358.
18. Mozaffarian D., Geelen A., Brouwer I.A. et al. Effect of Fish Oil on Heart Rate in Humans: A Meta-Analysis of Randomized Controlled Trials // Circulation, September 27, 2005; 112(13): 1945-1952.
19. McLennan PL. Myocardial membrane fatty acids and antiarrhythmic actions of dietary fish oil in animal models // Lipids. 2001; 36: 111S-114S.
Review
For citations:
Antonchenko I.V., Tatarskiy B.A., Rodionov V.A., Batalov R.E., Savenkova G.M., Borisova E.V., Biserova I.N., Popov S.V. USE OF Ω-3 POLYUNSATURATED FATTY ACIDS FOR TREATMENT OF PAROXYSMAL ATRIAL FIBRILLATION. Journal of Arrhythmology. 2008;53(53):5-11. (In Russ.)